TrialGynecologic oncology2013

A phase II evaluation of gefitinib in the treatment of persistent or recurrent endometrial cancer: a Gynecologic Oncology Group study.

Kimberly K Leslie et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.